ProtaGene appoints Raymond Kaiser as CEO
Germany-based ProtaGene GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and gene therapy, announced the appointment of Raymond Kaiser, PhD, as Chief Executive Officer.
Kaiser joined the company earlier this year as Chief Operating Officer.
With the recently completed merger with GeneWerk and partnership with healthcare growth investor Ampersand Capital Partners, ProtaGene will continue building its team and capabilities to support today's increasingly complex therapeutic development programs.
"ProtaGene is incredibly well-positioned to serve as an analytical leader that supports the development of diverse therapeutic modalities," said Martin Blüggel, founder and former CEO, who remains engaged on the Board of Directors.
"It has been an extraordinary experience building the company, and now on the 25th anniversary, I entrust Ray, an experienced executive, to lead ProtaGene to future success. With growing operations in North America and Europe, the company under Ray's leadership is well prepared to serve our international sponsors within the biologics and cell and gene therapy sectors."
